Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 fatty acids in children and adolescents with ASD
NCT01248130Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2009
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omega-3-acid triglycerides in Autism Spectrum Disorder (ASD), sponsored by Massachusetts General Hospital. Primary endpoint: Social Responsiveness Scale at 12 weeks. Started Nov 2009; status: terminated.
02
Drugs
omega-3-acid triglycerides
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT01248130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01248130.